<DOC>
	<DOC>NCT01419691</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).</brief_summary>
	<brief_title>Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Leukemia, Prolymphocytic</mesh_term>
	<mesh_term>Auranofin</mesh_term>
	<criteria>histologically confirmed Bcell chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia arising from CLL/SLL or Richter's transformation according to WHO criteria who require therapy based on the 2008 revised IWCLL criteria. Relapsed or refractory disease after receiving at least 1 prior therapy for CLL At least 18 years old; ECOG status of 1 or less; life expectancy 2 months or greater Adequate organ and marrow function (total bilirubin less than 1.5x IULN; ALT less than 2x IULN; serum creatinine less than 1.5x ULN) have had chemotherapy, radiotherapy or immunotherapy within 4 weeks prior to entering study have not recovered from AEs due to agents administered more than 4 weeks prior receiving any other investigational agent known second malignancy that limits survival to less than 2 years known HIV positive uncontrolled intercurrent illness pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>auranofin</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>relapsed</keyword>
	<keyword>refractory</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>PLL</keyword>
</DOC>